Switzerland· 65970001
Alecensa
A alectinib product containing alectinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Alectinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED03 (alectinib), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Alectinib · ATC L01ED03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alectinib costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- Switzerland: $204.18 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Alectinib · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$204.18
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- alectinibum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01ED03
- ATC class
- Alectinib
- Defined daily dose
- 1.2 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680659700013224 StkCHF 4741.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
96 interactions on record for alectinib.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alectinib · interactions on record
96 records
- 10 severe
- 86 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- Aminolevulinic acidL01XD04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alectinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainALECENSA 150 MG CAPSULAS DURASRoche Registration Gmbh
- United StatesALECENSAGenentech, Inc.
- CzechiaALECENSARoche Registration GmbH, Grenzach-Wyhlen
- United KingdomAlecensa 150mg capsulesRoche Products Ltd
- BelgiumAlecensa 150 mgRoche Registration
- IcelandAlecensaRoche Registration GmbH*
- NetherlandsAlecensa 150 mg, harde capsuleRoche Registration GmbH
- NorwayAlecensaRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Alecensa
- Liechtenstein · Alecensa
- Norway · Alecensa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0e61bfc9-4a6a-42e2-a77d-8fd040b9d6ec GET /v1/drugs/0e61bfc9-4a6a-42e2-a77d-8fd040b9d6ec?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "alectinibum 150 mg",
"valid_from": "2024-11-01",
"limitations": "[{\"description\":\"<b>Behandlung von lokal fortgeschrittenem oder metastasiertem NSCLC</b><br>\\nNach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nALECENSA wird vergütet zur Behandlung von Patienten mit lokal fortgeschrittenem oder metastasiertem ALK (Anaplastic-lymphoma-kinase)-positivem nicht-kleinzelligem Lungenkarzinom (NSCLC) als Monotherapie. Im Falle einer Progression ist die Behandlung abzubrechen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-11-01\",\"validTo\":null}]",
"galenic_form": "Kaps 150 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2017-08-01",
"self_retention_pct": 10
}See everything about alectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.